A House hearing on bipartisan drug pricing reform bills continues the intense focus on the role of pharmacy benefit managers. But it also shows continued interest in finding ways to make payment systems work for cutting edge gene therapies.
A recent hearing on health cost transparency in the House Energy & Commerce/Health Subcommittee nicely captured the two extremes in play during the current Congressional efforts to further address drug pricing in the US.
The broadly focused hearing looked at new fewer than 17 different bills that would touch on essentially all aspects of the fragmented US system, with provisions ranging from efforts to increase price transparency for diagnostic tests to a series of measures
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.
A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.
At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
